Senior Scientist, Downstream Process Development (Contract)

• Perform pilot scale downstream purification process and manufacturing (post cell lysate to final formulation) by utilizing column chromatography, UFDF, and various filtration steps.
• Follow good documentation practices to maintain accurate records.
• Work closely with team members to perform buffer preparation.
• Set-up, operate and maintain required downstream laboratory equipment.
• Maintain reagent, sample, and consumables inventory.
• Assist with data entry and data analysis in Excel and/or other statistical programs.
• Ensure safe workplace in compliance with the company and EHS' rules and regulations.
• Work with Assay Development and Quality Control to coordinate testing.
• Work to optimize, and revise current process protocols, procedures, and batch records to make them more robust and streamlined.

• Bachelor’s or advanced degree in chemical/biochemical engineering or related fields.
• 6-8 years of downstream purification experience in pharmaceutical or gene therapy manufacturing, including GMP-regulated operations.
• Hands on experience with buffer preparations, TFF (Hollow Fiber/Cassettes), UF/DF and Column Chromatography Purification. Experience working with AKTA Avant is required.
• Able to work in a fast-paced environment as a team player with effective communication skills.
• Excellent computer skills; especially proficient in Excel and Word.
• Experience with statistical analysis software (e.g., JMP) and data visualization tools is a plus.
• Strong desire to learn new technologies, skill sets, and science behind AAV processing.
• Strong teamwork and communication skills.
• Familiarity with regulatory guidelines and requirements for biologics manufacturing is a plus.
• Some overtime required, as needed.

Adverum, a wholly owned subsidiary of Eli Lilly and Company, is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.

At Adverum, Inclusion and Diversity are at our core. We believe in the power of being your authentic self.  We strive to create the space which allows for everyone in our Adverum Community to not only feel safe but encouraged to speak, learn from each other, grow in their professions and be the very best versions of themselves no matter what their age, ethnic background, gender, origin, religion or sexual orientation.